^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABV-1501

    i
    Other names: ABV-1501, BLEX-404 for TNBC, BLI-1401-2
    Associations

    News

    Trials
    Company:
    ABVC BioPharma
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    1year
    Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov)
    P1/2, N=44, Not yet recruiting, BioLite, Inc. | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    docetaxel • ABV-1501
    almost2years
    Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov)
    P1/2, N=44, Not yet recruiting, BioLite, Inc. | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    docetaxel • ABV-1501